VEANA THERAPEUTICS LLC
Portland, OR · Biotech · Private
a-TEA-Lysine (a-TEA-Lys), a novel small-molecule therapeutic that induces cancer cell apoptosis while stimulating anti-tumor immunity
veana-therapeutics.com →- Grants
- $1.5M
- 5 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Title: Pre-clinical Evaluation of a Novel Immune Modulator, Alpha-TEA in Combination with Immune Checkpoint Blockade | $299,607 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Title: Pre-clinical Evaluation of a Novel Immune Modulator, Alpha-TEA in Combination with Immune Checkpoint Blockade | $350,128 | |
| Federal grant | Department of Health and Human Services · Phase I · Title: Pre-clinical Evaluation of a Novel Immune Modulator, Alpha-TEA in Combination with Immune Checkpoint Blockade | $50,521 | |
| Federal grant | Department of Health and Human Services · Phase I · Pre-clinical Evaluation of a Novel Immune Modulator, Alpha-TEA-Lys in Combination with Trastuzumab Against HER2/neu Positive Breast Cancer | $399,999 | |
| Federal grant | Department of Health and Human Services · Phase I · Pre-clinical Evaluation of a Novel Immune Modulator, Alpha-TEA-Lys in Combination with Trastuzumab Against HER2/neu Positive Breast Cancer | $399,999 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3052 | OLFA THERA, INC. | — | — |
| 3053 | Pharmareview Corporation | — | — |
| 3054 | BIOSETTIA, INC. | — | — |
| 3055 | VEANA THERAPEUTICS LLC | — | — |
| 3056 | NANONEWRON LLC | — | — |
| 3057 | CatalYm | — | — |
| 3058 | TFC BIOSCIENCES, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.